Rua Bioscience Share Price: A 3-Cent Medicinal Cannabis Bet With Real Revenue Growth
Rua Bioscience Share Price Today
The Rua Bioscience share price sits at about $0.03 NZD (NZX: RUA) in mid-June 2026, up roughly 23% over the past year. With a market cap near $10 million, Rua is a small Gisborne-based medicinal-cannabis company that has moved from a near-zero revenue base to delivering genuine, fast top-line growth, though it is not yet profitable.
Note that despite the similar name, this is a different company from the gold explorer RUA Gold (NZX: RGI). Rua Bioscience is a healthcare and cannabis-products business.
What Rua Bioscience Does
Rua Bioscience develops, manufactures, and sells medicinal-cannabis products. It has built a portfolio of products and is expanding internationally, recently reporting 17 products across 5 different markets, which gives it useful revenue diversification for a company its size. It has also established RUA Genetics in Canada, a milestone in building its supply and product pipeline.
Medicinal cannabis is a young, regulated, fast-evolving industry. Rua is a play on that market maturing, both in New Zealand and in export markets, with all the regulatory complexity that implies. As a small health-products company, it shares some of the brand-and-export challenges of natural-health names like Comvita and science-led Blis Technologies.
Recent Performance: Strong Growth, Still Lossmaking
Rua's revenue trajectory is encouraging:
- •FY25 revenue of about $1.9 million, up sharply from $322,000 the year before
- •Half-year revenue of about $1.33 million (to around December 2025), up 92% on the prior corresponding period
- •A forecast to exceed $3 million in full-year revenue
- •A capital raise (around $2 million) aimed at reaching financial self-sustainability
The growth rates are high, but off a tiny base, and the company remains lossmaking, hence the negative P/E and the need to raise capital. The reference to self-sustainability is telling: Rua is racing to reach the scale where revenue covers costs before it needs to keep tapping shareholders.
Key Metrics
- •Share price: ~$0.03 NZD
- •Market cap: ~$10 million NZD
- •52-week move: about +23%
- •FY25 revenue: ~$1.9 million (forecast >$3 million)
- •P/E ratio: not meaningful (lossmaking)
- •Net tangible assets: ~$0.010 per share
- •Gross dividend yield: 0%
What to Watch
- •Path to self-sustainability: The central question is whether revenue growth reaches the point where the business funds itself. Watch the loss narrowing and cash burn.
- •Export and regulatory progress: New markets and regulatory approvals expand the opportunity. Setbacks do the opposite.
- •Capital raises and dilution: As a lossmaking micro-cap, further raises are likely. Watch how much existing holders are diluted.
- •Product and channel growth: 17 products across 5 markets is good diversification; continued expansion is the growth engine.
The Bottom Line
Rua Bioscience is a small but genuinely growing medicinal-cannabis company, with fast revenue growth, international diversification, and a clear push toward self-sustainability. The bull case is exposure to a maturing medicinal-cannabis market via a company finally building real sales. The bear case is the familiar micro-cap profile: still lossmaking, tiny absolute revenue, reliant on capital raises and dilution, and exposed to a complex regulatory environment. This is a speculative growth stock for risk-tolerant investors who believe Rua can reach profitable scale.
For how we evaluate early-stage, lossmaking growth companies, see our methodology.
*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*